AstraZeneca pens agentic AI licensing deal with Owkin

AstraZeneca is the latest Big Pharma company looking to tap into agentic artificial intelligence (AI), inking a three-year licensing deal with Owkin to leverage its autonomous “AI Scientist” platfo AstraZeneca is the latest Big Pharma company looking to tap into agentic artificial intelligence (AI), inking a three-year licensing deal with Owkin to leverage its autonomous “AI Scientist” platform. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report…

Source: FierceBiotech